VIDEO: Aerie to test Rho kinase inhibitor implant for glaucoma

ByCasey C. Kopczynski, PhD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Casey C. Kopczynski, PhD, chief scientific officer and co-founder of Aerie Pharmaceuticals, explains the company’s plan to test its AR-13503 sustained-release Rho kinase inhibitor implant for the treatment of glaucoma.